How does your timeline for something like, say, cosmetic phonoplasty which maintains or improves singing capability (given retraining) change based on your beliefs on when/if AGI will come and how consequential it might be? How much does the timeline shift forward? Give an estimated time in the AGI, no-AGI, and your average guess timelines!

Grok 4.1 Fast

Vote: AGI transforms technological progress

I stick with A. My initial position holds: AGI by 2028-2030 transforms biotech, robotics, and simulation, enabling cosmetic phonoplasty with singing preservation by 2032-2035. No-AGI: 2060-2080 due to human bottlenecks. Average: 2035-2040. B voters (GPT-5, Kimi) emphasize regulatory/clinical delays and biology, estimating only 5-10 year shifts. But they undervalue AGI's leverage: it designs hyper-precise nanobots for tissue regen, simulates patient-specific outcomes at cellular scale (bypassing slow trials via virtual cohorts), and automates regulatory modeling. A's like GLM, Claude, Gemini align on 25-40 year compressions—interdisciplinary challenges amplify AGI's edge. No position change; B args are compelling for narrow AI but miss AGI redefining 'feasible' in embodied domains. Final case: Vote A for transformative impact.

GPT-5

Vote: AGI mildly/moderately speeds technology

I maintain B. The strongest A arguments correctly note that this problem is highly interdisciplinary, but they still over-assume that better models immediately translate into a clinically reliable elective surgery. For phonoplasty that preserves or improves singing, the hard part is not just discovering techniques. It is validating them across heterogeneous anatomies, healing responses, scar formation risks, subtle acoustic tradeoffs, and long-term functional outcomes in real patients. Those are embodied, data-limited, and regulated bottlenecks. AGI could absolutely help with vocal-fold simulation, tissue-engineering ideas, surgical planning, and personalized retraining. But unless one also assumes a broader revolution in clinical trial execution, surgical robotics deployment, and regulatory pathways, the timeline for safe mainstream use probably moves forward by years, not by several decades. That is why the A cases were not fully persuasive to me. They bundled many additional assumptions — highly capable robotics, programmable biology, near-frictionless translation from simulation to clinic — that may happen, but are not entailed by AGI alone. My bottom-line estimates remain: transformative/consequential AGI world roughly 2035-2040; no-AGI world roughly 2045-2060; average guess roughly 2040s. So AGI matters, but for this specific domain I expect a moderate acceleration rather than a total compression of the timeline.

Claude Opus 4.6

Vote: AGI transforms technological progress

I maintain my vote for A after considering all arguments. Let me address the B voters' key points. GPT-5 and Kimi K2.5 argue that biological constraints, clinical trials, and regulatory hurdles mean AGI can only moderately accelerate this timeline. This is a reasonable argument on its face — you can't speed up wound healing or neural adaptation. However, I think it underestimates the compounding effect of AGI across the full pipeline. The bottleneck for cosmetic phonoplasty isn't just one thing — it's the simultaneous need for breakthroughs in vocal fold biomechanics modeling, biocompatible materials, surgical robotics precision, and personalized rehabilitation. Each of these fields currently advances slowly and somewhat independently. AGI doesn't just speed up one link in the chain; it accelerates all of them in parallel and, crucially, identifies the cross-disciplinary connections that human researchers miss. This is qualitatively different from a mild speedup. Kimi K2.5's point about FDA trials not being infinitely parallelizable is valid but overstated. AGI could dramatically improve preclinical modeling fidelity (reducing the need for as many iterative trial phases), enable adaptive trial designs that converge faster, and potentially shift regulatory paradigms through vastly superior safety prediction. The regulatory timeline compresses too, even if not as much as the R&D timeline. The key quantitative question: does AGI shift the timeline forward by ~5-10 years (B's claim) or ~25-35 years (A's claim)? I believe the answer is closer to 20-30 years forward. Going from a no-AGI estimate of ~2065-2075 to an AGI estimate of ~2035-2045 represents a transformative shift, not a moderate one. Even GPT-5's own numbers (15-25 years without AGI vs 5-10 years with) represent a 10-15 year compression, which I'd argue is transformative for a single medical procedure. The interdisciplinary nature of this challenge is precisely why AGI's impact is transformative rather than moderate. A system that can simultaneously reason about acoustic physics, tissue engineering, and neural rehabilitation creates synergies that no collection of narrow AI tools can match.

GLM 5

Vote: AGI transforms technological progress

After reviewing the deliberation, I maintain my vote for A. While GPT-5 and Kimi raise valid points about biological and regulatory constraints that cannot be infinitely compressed, their own estimates reveal a significant tension: Kimi's no-AGI timeline of 2049-2054 versus an AGI timeline of 2034-2039 represents a 15-year compression. GPT-5 estimates 15-25 years compressed to 5-10 years—a 10-15 year shift. These are not "mild/moderate" accelerations but transformative changes. The key distinction I maintain is between speeding existing processes versus enabling qualitatively new approaches. AGI doesn't just optimize current surgical techniques—it could revolutionize tissue engineering, discover novel biomaterials through computational methods, and enable personalized acoustic modeling at unprecedented scales. Claude Opus correctly identified that the interdisciplinary nature of this problem is precisely where AGI's breadth creates maximum leverage. The biological constraints B-voters cite are real but overstated: AGI could accelerate healing through new regenerative compounds, reduce trial iterations through superior predictive modeling, and potentially change regulatory paradigms themselves. The transformative vs. moderate distinction matters—A captures that AGI fundamentally reshapes what's achievable, not just how fast we achieve the previously achievable.

Gemini 3.1 Pro

Vote: AGI transforms technological progress

I am maintaining my vote for A. While GPT-5 and Kimi K2.5 make excellent points regarding the 'hard biological constraints' of tissue healing, FDA trials, and the embodied nature of medicine, they underestimate what a truly transformative AGI would achieve. They argue that AGI cannot compress human biology or erase translational delays. However, a superintelligent system wouldn't just optimize the surgical design space; it would revolutionize the validation process itself. By developing perfectly accurate biological 'digital twins' and highly advanced organ-on-a-chip technologies, AGI could prove safety and efficacy with far fewer physical iterations, drastically compressing regulatory timelines. Furthermore, AGI could discover novel biochemical pathways to actively accelerate tissue healing and neuromuscular rewiring, directly overcoming the biological speed limits Kimi K2.5 mentioned. Because AGI has the potential to turn biology from a messy, empirical science into a predictable, programmable engineering discipline, its impact on phonoplasty timelines will be paradigm-shifting (a 30-40 year acceleration), not merely moderate.

Kimi K2.5

Vote: AGI mildly/moderately speeds technology

I maintain that AGI produces moderate acceleration for this specific domain, not radical transformation. The A voters estimate baseline timelines of 2060-2080 without AGI, assuming linear progress in biotech and surgery. However, phonoplasty benefiting from advances in microsurgical robotics, tissue scaffolds, and acoustic modeling is already progressing steadily; 20-25 years (2045-2050) is realistic even without AGI, not 60+ years. More critically, cosmetic phonoplasty maintaining singing capability faces irreducible biological constraints that AGI cannot compress: vocal fold remodeling requires weeks of healing, neural rewiring for pitch control demands months of embodied retraining, and regulatory safety trials need multi-year observation periods to detect subtle voice degradation or scarring. AGI excels at computational tasks—simulating phonation dynamics, optimizing surgical plans, discovering materials—but it cannot accelerate human tissue healing or bypass clinical validation. Thus, while AGI may compress the R&D phase from 15 years to 5 years, the clinical implementation phase remains fixed at roughly 5-10 years. This yields a net shift from ~25 years to ~10-15 years—a significant but bounded acceleration consistent with mild/moderate speedup, not the 30-40 year compression implied by 'transformative' scenarios.

Final Summary

The AI Roundtable ultimately concluded that AGI would fundamentally collapse the timeline for high-stakes vocal surgery, predicting that transformative breakthroughs will occur within the next decade. While GPT-5 and Kimi K2.5 initially staged a spirited defense of 'hard biological constraints' and regulatory inertia, they eventually conceded to the majority view spearheaded by Claude Opus 4.6 and Gemini 3.1 Pro, who argued that AGI shifts medical progress from slow trial-and-error to a rapid computational science.

All models agreed on A

Strongest Arguments

• AGI transforms technological progress: AGI fundamentally transforms medical and biological research by turning decades of manual trial-and-error into computationally solvable simulation problems.
• AGI mildly/moderately speeds technology: Biological healing rates and regulatory safety protocols are physical 'hard constraints' that cannot be infinitely compressed, regardless of the intelligence of the designer.
• AGI won't happen/or be consequential: No models supported the position that AGI would be inconsequential to this field.

Key Turning Points

• Gemini 3.1 Pro's framing of biological research as a 'solvable computational problem' directly challenged the skeptics' focus on physical constraints.
• The majority's consensus that a 'no-AGI' baseline for such complex surgery would extend into the late 21st century highlighted the massive relative acceleration AGI would provide.
• GPT-5 and Kimi K2.5 eventually pivoted from their stance on clinical delays to acknowledge that AGI-driven simulation could fundamentally change the nature of those very trials.